DGKB and Kaposi's sarcoma: Indeed, the DGK pharmacological inhibitor R59949 strongly reduces hepatocyte growth factor (HGF)-induced KS proliferation and anchorage-independent growth without affecting cell survival or the classical Akt and MAPK pathways, which are usually implicated in KS.